Kura Oncology (KURA) Getting Somewhat Positive Press Coverage, Accern Reports
Media stories about Kura Oncology (NASDAQ:KURA) have been trending somewhat positive on Sunday, according to Accern Sentiment. The research firm identifies negative and positive news coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Kura Oncology earned a media sentiment score of 0.22 on Accern’s scale. Accern also gave media stories about the company an impact score of 45.2193727291095 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Here are some of the news articles that may have effected Accern Sentiment’s rankings:
- Kura Oncology (KURA) Rating Increased to Hold at BidaskClub (americanbankingnews.com)
- Wedbush Rates Kura Oncology Outperform As Catalysts Loom (finance.yahoo.com)
- Kura Oncology (KURA) Research Coverage Started at Wedbush (americanbankingnews.com)
- Kura Oncology Added to Nasdaq Biotechnology Index (finance.yahoo.com)
A number of equities research analysts have issued reports on KURA shares. Wedbush started coverage on Kura Oncology in a research report on Wednesday. They issued an “outperform” rating and a $19.00 price target on the stock. Zacks Investment Research downgraded Kura Oncology from a “buy” rating to a “hold” rating in a report on Wednesday, October 18th. Oppenheimer set a $18.00 price objective on Kura Oncology and gave the company a “buy” rating in a report on Monday, December 11th. Citigroup increased their price objective on Kura Oncology from $15.00 to $19.00 and gave the company a “buy” rating in a report on Thursday, November 9th. Finally, Cann reiterated a “buy” rating and issued a $17.50 price objective on shares of Kura Oncology in a report on Monday, December 11th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and six have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $18.08.
Kura Oncology (NASDAQ:KURA) last released its quarterly earnings results on Tuesday, November 7th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.01). analysts expect that Kura Oncology will post -1.5 earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: “Kura Oncology (KURA) Getting Somewhat Positive Press Coverage, Accern Reports” was published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be accessed at https://theolympiareport.com/2017/12/24/kura-oncology-kura-getting-somewhat-positive-press-coverage-accern-reports.html.
About Kura Oncology
Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.